Evidence map›Paper›PMID 26710887›Full record

ReviewLeukemia2016

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.

J Laubach, L Garderet, A Mahindra, G Gahrton, J Caers, O Sezer, P Voorhees, X Leleu, H E Johnsen, M Streetly and 30 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Prognostic value ofClinical and experimental medicine · 2023
    Pooled it
  2. Pooled it
  3. How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020
    Pooled it
  4. Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2020
    Pooled it
  5. Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018
    Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

J LaubachDana-Farber Cancer Institute, Boston, MA, USA.
L GarderetHôpital Saint Antoine, Paris, France.
A MahindraUniversity of California San Francisco, San Francisco, CA, USA.
G GahrtonKarolinska Institutet, Center for Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden.
J CaersDepartment of Hematology, CHU Liège, Belgium.
O SezerMemorial Hospital, Hematology Department, Istanbul, Turkey.
P VoorheesLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
X LeleuMaladies du sang, hôpital Huriez, CHRU, Lille, France.
H E JohnsenAalborg University Hospital, Aalborg, Denmark.
M StreetlyKing's College Hospital, London, UK.
A JurczyszynJagiellonian University Medical College, Kraków, Poland.
H LudwigWilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria.
U-H MellqvistSahlgrenska University Hospital, Gothenburg, Sweden.
W-J ChngCancer Science Institute, National University of Singapore, Singapore, Republic of Singapore.
L PilarskiUniversity of Alberta and Cross Cancer Institute, Edmonton, Canada.
H EinseleDepartment of Internal Medicine II, Division of Hematology, University Hospital of Würzburg, Würzburg, Germany.
J HouThe Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, Shanghai, China.
I TuressonSkano University Hospital, Malmo, Sweden.
E Zamagni"Seràgnoli" Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
C S ChimDepartment of Medicine, Queen Mary Hospital, Hong Kong, China.
A MazumderNYU Comprehensive Cancer Center, New York, NY, USA.
J WestinSahlgrenska University Hospital, Gothenburg, Sweden.
J LuPeking University People's Hospital, Beijing, China.
T ReimanSaint John Regional Hospital and Dalhousie University, Saint John, NB.
S KristinssonKarolinska Institutet, Center for Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden.
D JoshuaRoyal Prince Alfred Hospital, Camperdown, Australia.
M RousselHématologie clinique, hôpital Purpan, Toulouse, France.
P O'GormanNational Institute for cellular Biotechnology, Dublin City University, Dublin, Ireland.
E TerposNational and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
P McCarthyBlood and Marrow Transplant Program, Roswell Park Cancer Institute, Buffalo, NY, USA.
M DimopoulosNational and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
P MoreauUniversity Hospital Hotel-Dieu, Nantes, France.
R Z OrlowskiDepartment of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J S MiguelCentro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, Pamplona, Spain.
K C AndersonDana-Farber Cancer Institute, Boston, MA, USA.
A PalumboDepartment of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.
S KumarMayo Clinic, Rochester, MN, USA.
V RajkumarMayo Clinic, Rochester, MN, USA.
B DurieCedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA.
P G RichardsonDana-Farber Cancer Institute, Boston, MA, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
6 · The paper itself

Abstract

The prognosis for patients multiple myeloma (MM) has improved substantially over the past decade with the development of new, more effective chemotherapeutic agents and regimens that possess a high level of anti-tumor activity. In spite of this important progress, however, nearly all MM patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed MM thus represents a vital aspect of the overall care for patients with MM and a critical area of ongoing scientific and clinical research. This comprehensive manuscript from the International Myeloma Working Group provides detailed recommendations on management of relapsed disease, with sections dedicated to diagnostic evaluation, determinants of therapy, and general approach to patients with specific disease characteristics. In addition, the manuscript provides a summary of evidence from clinical trials that have significantly impacted the field, including those evaluating conventional dose therapies, as well as both autologous and allogeneic stem cell transplantation. Specific recommendations are offered for management of first and second relapse, relapsed and refractory disease, and both autologous and allogeneic transplant. Finally, perspective is provided regarding new agents and promising directions in management of relapsed MM.

Indexed as

Multiple MyelomaPractice Guidelines as TopicAntineoplastic AgentsDisease ManagementHematopoietic Stem Cell TransplantationHumansRecurrenceSalvage TherapyAntineoplastic Agents

Identifiers

PMID26710887

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.